Modest reductions in dose intensity and drug-induced neutropenia have no major impact on survival of patients with non-small cell lung cancer treated with platinum-doublet chemotherapy

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
Andre T BrunettoMary E R O'Brien

Abstract

Previous studies investigating the effect of increased dose intensity and chemotherapy-induced neutropenia in patients with advanced non-small cell lung cancer (NSCLC) have not consistently shown significant survival benefits. This retrospective analysis reviewed the outcome of patients receiving palliative chemotherapy for advanced NSCLC (stages III-IV) at the Royal Marsden Hospital. Regimens included cisplatin or carboplatin with either vinorelbine or gemcitabine on days 1 and 8, every 21 days. Patients who received at least four cycles of chemotherapy were classified into groups based on dose intensity, dose reductions, and worst grade of neutropenia for a landmark analysis. Comparisons between these groups for time to progression and overall survival were made by standard univariate and multivariate methods. One hundred sixty-nine of a total of 190 patients who received more than four cycles of chemotherapy during the period between November 1998 and December 2008 were included. One hundred twenty-five (73.9%) patients received four chemotherapy cycles with the remaining receiving up to six cycles. The median relative dose intensity for platinum was 93.9% (62.1-102%) and for vinorelbine/gemcitabine was 91.7% (37.8-105%). Do...Continue Reading

References

Jun 12, 2002·Current Treatment Options in Oncology·Primo N LaraDavid R Gandara
Feb 9, 2005·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Richard J Gralla, Nick Thatcher
Mar 22, 2005·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·C TibaldiUNKNOWN POLTO group
May 12, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anthony J AlbergJonathan M Samet
Feb 16, 2006·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Jean-Louis PujolJean-Pierre Daurès
Sep 8, 2006·The New England Journal of Medicine·Ken A OlaussenUNKNOWN IALT Bio Investigators
Oct 20, 2006·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Udai BanerjiMary O'Brien
Jul 3, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·George SimonGerold Bepler

❮ Previous
Next ❯

Citations

Nov 20, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M KreuterUNKNOWN TREAT investigators
May 31, 2011·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·David J Stewart
Dec 3, 2014·Critical Reviews in Oncology/hematology·Laura J HavrileskyJeffrey Crawford
Feb 6, 2014·Indian Journal of Urology : IJU : Journal of the Urological Society of India·E Charles OsterbergRanjith Ramasamy
Jun 7, 2019·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Jeffrey CrawfordGary H Lyman
May 2, 2017·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Jeff A EngleJill M Kolesar
Sep 27, 2019·Journal of Managed Care & Specialty Pharmacy·Julia F SlejkoBruce Stuart
Aug 6, 2021·Therapeutic Advances in Medical Oncology·Antonin VaryAnthony Turpin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Squamous Cell

Basal cell carcinoma is a form of malignant skin cancer found on the head and neck regions and has low rates of metastasis. Discover the latest research on basal cell carcinoma here.